Want to see COCP full AI Analyst Report?
Top Page
Cocrystal Pharma
(NASDAQ:COCP)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.92
▲(2.44% Upside)
Action:Reiterated
Date:07/18/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses and cash burn, and a steep decline in equity that increases funding dependence). Technical indicators also reflect a downtrend and negative momentum (price below key moving averages, negative MACD, low RSI). Valuation is difficult to support with a negative P/E and no dividend yield provided.
Positive Factors
Structure-based discovery and broad-spectrum pipeline
Cocrystal’s structure-based platform has generated candidates with pan-viral activity by targeting conserved replication enzyme regions. This tech foundation supports multiple, differentiated programs and raises the prospect of durable, platform-driven pipeline expansion and partner interest across viral families.
Negative Factors
Pre-commercial profile with no revenue
Cocrystal remains pre-commercial with no product revenue and persistent losses. This structural reality makes company value contingent on clinical success or partnerships; absent revenue, operating sustainability depends on financing and milestone-driven funding rather than organic cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Structure-based discovery and broad-spectrum pipeline
Cocrystal’s structure-based platform has generated candidates with pan-viral activity by targeting conserved replication enzyme regions. This tech foundation supports multiple, differentiated programs and raises the prospect of durable, platform-driven pipeline expansion and partner interest across viral families.
Read all positive factors
Cocrystal Pharma (COCP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.96M
Dividend YieldN/A
Average Volume (3M)3.12M
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS Growth53.06%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.74
Shares Outstanding13,787,453
10 Day Avg. Volume178,720
30 Day Avg. Volume3,115,767
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside1011.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.67
Revenue Forecast (FY)N/A
Cocrystal Pharma Business Overview & Revenue Model
Company Description
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications,...
How the Company Makes Money
null...
Cocrystal Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.05M | -12.54M | -15.17M | -12.39M | -8.79M |
| EBITDA | -8.46M | -17.38M | -20.97M | -17.95M | -13.99M |
| Net Income | -8.83M | -17.50M | -17.98M | -38.84M | -14.19M |
Balance Sheet | |||||
| Total Assets | 9.71M | 13.46M | 31.26M | 40.84M | 79.39M |
| Cash, Cash Equivalents and Short-Term Investments | 7.03M | 9.86M | 26.35M | 37.14M | 58.70M |
| Total Debt | 1.50M | 1.81M | 1.85M | 297.00K | 534.00K |
| Total Liabilities | 3.38M | 3.93M | 4.88M | 1.27M | 1.84M |
| Stockholders Equity | 6.33M | 9.52M | 26.38M | 39.57M | 77.55M |
Cash Flow | |||||
| Free Cash Flow | -8.20M | -16.49M | -14.78M | -21.51M | -12.77M |
| Operating Cash Flow | -8.19M | -16.48M | -14.67M | -21.43M | -12.72M |
| Investing Cash Flow | -12.00K | -8.00K | -118.00K | -74.00K | -52.00K |
| Financing Cash Flow | 5.37M | 0.00 | 3.99M | -27.00K | 38.47M |
Cocrystal Pharma Technical Analysis
Negative
0.90
Price Trends
1.00
Negative
1.14
Negative
1.09
Negative
Market Momentum
-0.04
Positive
31.82
Neutral
6.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COCP, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 1.00, and below the 200-day MA of 1.09, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 31.82 is Neutral, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COCP.
Cocrystal Pharma Risk Analysis
Cocrystal Pharma disclosed 53 risk factors in its most recent earnings report. Cocrystal Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cocrystal Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $20.22M | -0.35 | -264.79% | ― | ― | 58.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $11.96M | -1.11 | -150.61% | ― | ― | 53.06% | |
44 Neutral | $7.68M | -1.93 | -43.95% | ― | 11.90% | 43.46% | |
41 Neutral | $5.75M | -0.17 | -423.84% | ― | -8.47% | 25.61% | |
38 Underperform | $10.79M | -1.03 | -101.09% | ― | ― | 79.70% |
* Healthcare Sector Average
COCP
Cocrystal Pharma
0.82
-1.03
-55.68%
CLRB
Cellectar Biosciences
2.57
-2.15
-45.55%
IMRN
Immuron
1.09
-0.56
-33.94%
BRTX
BioRestorative Therapies
0.20
-1.21
-85.53%
BIVI
BioVie
1.52
-4.51
-74.79%
Cocrystal Pharma Corporate Events
Executive/Board ChangesShareholder Meetings
Cocrystal Pharma Shareholders Approve Governance and Oversight Measures
Positive
Jul 17, 2026
On July 14, 2026, Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on key governance and oversight matters. The meeting covered the election of board members, ratification of the independent auditor for...
Business Operations and StrategyExecutive/Board Changes
Cocrystal Pharma Appoints New CEO to Lead Transition
Positive
Jun 9, 2026
On June 3, 2026, Cocrystal Pharma appointed industry veteran James Sapirstein as Chief Executive Officer, replacing former Co-CEOs Sam Lee and James Martin, who remain in their roles as President/Chief Scientific Officer and Chief Financial Office...
Business Operations and StrategyExecutive/Board Changes
Cocrystal Pharma Names New CEO to Drive Antiviral Pipeline
Positive
Jun 3, 2026
Cocrystal Pharma has appointed biopharma executive James Sapirstein as Chief Executive Officer, effective June 3, 2026, as the company advances multiple clinical antiviral programs built on its structure-based drug discovery platform. He succeeds ...
Business Operations and StrategyProduct-Related Announcements
Cocrystal Pharma Reports Promising Pan-Viral Antiviral Activity
Positive
May 26, 2026
On May 26, 2026, Cocrystal Pharma announced that its novel direct-acting antiviral molecules have shown pan-viral activity in vitro against multiple pathogens, including hantaviruses, bunyaviruses and influenza viruses, by targeting a highly conse...
Business Operations and StrategyProduct-Related Announcements
Cocrystal Showcases Norovirus Candidate CDI-988 at ICAR 2026
Positive
Apr 30, 2026
On April 30, 2026, Cocrystal Pharma announced that its first oral protease inhibitor CDI-988 for norovirus prevention and treatment was highlighted in an oral presentation at the 39th International Conference on Antiviral Research in Prague, under...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.